use
vaccin
save
million
live
everi
year
across
globe
number
import
diseas
hivaid
malaria
tb
hepat
c
continu
frustrat
attempt
produc
effect
vaccin
confront
challeng
requir
new
approach
increas
research
effort
scientif
commun
sixth
framework
programm
european
commiss
ec
import
catalyst
direct
alloc
financi
contribut
eur
million
wide
varieti
vaccin
research
activ
rang
basic
vaccinolog
translat
research
clinic
applic
vaccin
taken
togeth
around
research
group
countri
particip
vaccin
activ
impress
number
signal
new
spirit
collabor
research
facilit
exploit
immens
possibl
modern
vaccinolog
vaccin
work
present
antigen
immun
system
respond
evok
immun
respons
amelior
effect
infecti
pathogen
diseas
process
vaccin
either
prophylact
therapeut
antigen
materi
either
live
attenu
pathogen
kill
inactiv
form
pathogen
purifi
recombin
materi
protein
vaccin
research
seen
remark
renaiss
last
decad
partli
catalyz
scientif
correspond
author
tel
fax
breakthrough
full
genom
sequenc
sever
infecti
pathogen
refin
knowledg
human
immun
respons
system
new
breakthrough
understand
hostpathogen
interact
major
factor
signific
influx
money
public
fund
bodi
privat
chariti
organis
commerci
enterpris
privat
sector
recent
commerci
success
human
papilloma
viru
hpv
vaccin
trigger
small
even
larg
pharmaceut
compani
initi
renew
interest
vaccin
trend
support
appear
novel
financ
mechan
product
develop
partnership
pdp
introduct
marketrel
incent
vaccin
fund
advanc
market
commit
amc
intern
financ
facil
vaccin
sever
reason
public
sector
engag
activ
vaccin
research
support
develop
new
see
front
matter
elsevi
ltd
right
reserv
vaccin
firstli
vaccin
one
effect
way
protect
peopl
infecti
diseas
therebi
activ
promot
better
health
qualiti
life
local
well
global
secondli
vaccin
one
costeffect
measur
public
health
safe
effect
prophylact
vaccin
significantli
costeffect
repeat
applic
drug
treatment
vaccin
therefor
releas
resourc
use
elsewher
health
system
thirdli
develop
vaccin
extraordinari
pathogen
hiv
may
technic
scientif
challeng
may
never
occur
without
sustain
support
activ
contribut
public
sector
address
challeng
pathogen
may
hand
lead
scientif
breakthrough
broader
impact
technolog
econom
develop
last
least
vaccin
pathogen
dengu
malaria
mainli
preval
lowincom
countri
unlik
develop
unless
public
sector
subsidis
support
research
respect
intern
public
organis
european
commiss
ec
particularli
import
role
play
act
higher
emphasi
global
health
agenda
rather
pure
commerci
nation
research
prioriti
europ
long
success
tradit
vaccin
research
public
privat
institut
twothird
global
vaccin
r
conduct
european
firm
almost
vaccin
product
take
place
europ
region
europ
therefor
well
posit
take
new
challeng
vaccin
research
exploit
immens
opportun
open
field
scienc
sixth
framework
programm
research
ec
adopt
gave
opportun
provid
momentum
vaccin
research
european
dimens
cours
eur
million
alloc
ec
initi
total
project
focu
vaccin
vaccinerel
research
tabl
project
cover
three
main
categori
research
sixteen
project
fund
develop
matur
highli
innov
technolog
new
vaccinolog
concept
project
name
fund
view
develop
vaccin
candid
specif
diseas
final
capac
build
clinic
investig
implement
research
exist
vaccin
receiv
total
fund
nearli
eur
million
support
project
addit
ec
contribut
eur
million
made
european
develop
countri
clinic
trial
partnership
edctp
initi
use
resourc
support
capac
build
clinic
trial
new
vaccin
treatment
hivaid
malaria
tb
subsaharan
africa
project
differ
magnitud
support
within
categori
research
largest
project
type
integr
project
ip
use
gather
multidisciplinari
consortia
suffici
critic
mass
translat
basic
research
applic
smaller
focus
research
activ
mostli
support
specif
target
research
project
strep
case
cooper
research
smalland
mediums
enterpris
coop
smaller
flexibl
strep
project
well
suit
earli
stage
research
wherea
larger
multidisciplinari
ip
may
act
take
new
discoveri
strep
project
also
deliv
matur
project
result
clinic
applic
downstream
develop
industri
organis
edctp
publicpriv
partnership
anoth
project
type
network
excel
noe
appli
area
special
tool
structur
coordin
european
research
commun
around
common
research
agenda
smallest
type
project
strateg
support
action
ssa
use
support
activ
harmon
research
standard
confer
workshop
train
scheme
research
basic
vaccinolog
support
eur
million
cours
fund
use
initi
research
consortia
focus
knowledg
technolog
broader
relev
vaccin
develop
project
cover
wide
rang
aspect
activ
area
receiv
particular
attent
name
mucos
vaccinolog
postgenom
vaccinolog
dendrit
cell
vaccin
target
mani
infecti
diseas
caus
pathogen
enter
human
bodi
mucos
surfac
includ
seriou
diseas
hivaid
tb
influenza
sexual
transmit
diseas
mani
diseas
may
better
confront
caus
pathogen
stop
first
port
entri
human
bodi
hypothesi
follow
muvapr
project
investig
effect
last
immun
respons
induc
mucos
surfac
muvapr
consortium
coordin
novarti
vaccin
project
compris
research
organis
public
sector
europ
biotech
industri
african
research
institut
project
start
decemb
sinc
explor
sever
new
approach
mucos
vaccin
provid
new
solut
overcom
technic
difficulti
sampl
human
mucos
immun
system
ethic
concern
undertak
mucos
studi
human
also
address
two
clinic
trial
involv
nasal
applic
success
complet
muvapr
consortium
complement
savinmucopath
project
aim
develop
mucosa
specif
vaccin
bacteri
infect
munanovac
project
explor
use
nanoparticl
mucos
immun
epivac
project
focus
transderm
immunis
taken
togeth
project
cover
wide
rang
research
deliveri
vaccin
new
rout
administr
total
ec
contribut
basic
vaccinolog
alloc
project
demonstr
import
area
within
ec
portfolio
vaccin
research
use
new
genom
data
better
select
candid
antigen
import
aspect
contemporari
vaccinolog
also
reflect
ec
portfolio
project
compuvac
project
gather
partner
joint
effort
develop
platform
ration
design
standard
evalu
genet
vaccin
bacab
project
aim
build
standard
approach
select
new
vaccin
candid
basi
structur
determin
togeth
microbearray
anoth
research
consortium
categori
project
repres
approxim
total
ec
fund
basic
vaccinolog
third
major
activ
area
basic
vaccinolog
potenti
use
dendrit
cell
facilit
immun
infecti
well
noninfecti
diseas
current
vaccin
work
induc
antibodi
respons
vaccin
diseas
aid
cancer
autoimmun
diseas
may
also
requir
concurr
cytotox
tcell
respons
integr
project
decvac
aim
understand
role
dendrit
cell
immun
system
use
knowledg
develop
broadli
applic
method
enhanc
antigen
uptak
present
dendrit
cell
dc
effort
decvac
complement
dcvacc
theravac
explor
potenti
futur
use
dendrit
cell
natur
adjuv
target
broad
rang
vaccin
besid
area
number
project
address
area
basic
vaccinolog
rang
use
new
vector
vaccin
develop
mvactor
establish
virtual
immun
system
immunogrid
project
basic
vaccinolog
thu
cover
wide
rang
activ
common
aim
establish
new
method
novel
technolog
futur
vaccin
research
across
rang
diseas
vaccin
research
activ
tightli
associ
singl
diseas
pathogen
case
collabor
project
receiv
total
ec
contribut
eur
mill
undertak
r
within
four
differ
group
diseas
fig
combat
major
povertyrel
diseas
prd
establish
prioriti
within
european
commiss
major
compon
therefor
support
vaccin
research
area
diseas
major
integr
project
receiv
ec
fund
eur
million
undertak
translat
research
activ
period
half
project
focus
hivaid
reflect
huge
challeng
vaccin
research
particular
area
avip
consortium
compris
research
group
europ
africa
aim
gener
novel
aid
vaccin
candid
base
combin
hiv
regulatori
tat
andor
rev
andor
nef
structur
env
andor
gagpol
protein
largest
malaria
project
emvda
aim
select
develop
test
candid
vaccin
direct
asexu
blood
stage
malaria
parasit
project
coordin
european
malaria
vaccin
initi
emvi
access
number
differ
synthet
antigen
glurp
eba
starp
flagship
tb
research
tbvac
consortium
join
public
privat
institut
european
african
countri
project
cover
preclin
earli
clinic
develop
subunit
vaccin
also
new
live
attenu
vaccin
rbcgurechli
mtbphop
collect
tbvac
consortium
therefor
compris
world
comprehens
portfolio
tb
vaccin
candid
current
develop
influenza
pandem
spanish
flu
kill
million
peopl
around
world
remind
new
viral
diseas
suddenli
appear
reappear
short
notic
dramat
consequ
recent
exampl
stem
novemb
sar
sever
acut
respiratori
syndrom
hitherto
unknown
infecti
diseas
report
guangdong
china
quickli
spread
hong
kong
taiwan
singapor
vietnam
canada
contain
event
underlin
import
support
vaccin
research
new
reemerg
infecti
diseas
exist
season
flu
vaccin
highli
effect
manag
influenza
thu
number
obstacl
develop
safe
effect
vaccin
pandem
influenza
vaccin
research
influenza
sar
initi
project
focus
pandem
influenza
increas
prepared
potenti
futur
outbreak
largest
project
fluvacc
develop
improv
technolog
quickli
produc
new
live
attenu
influenza
vaccin
base
revers
genet
around
million
carrier
approxim
newli
infect
everi
year
hepat
c
also
consid
emerg
threat
global
public
health
hepacivac
project
aim
develop
prophylact
potenti
therapeut
vaccin
hepat
c
viru
aim
project
undertak
formal
preclin
test
two
promis
vaccin
candid
subsequ
progress
earli
clinic
test
healthi
volunt
well
chronic
infect
individu
neglect
infecti
diseas
nid
receiv
littl
attent
media
public
comparison
high
profil
diseas
hivaid
malaria
tb
effect
diseas
nevertheless
devast
group
nid
clearli
defin
broadli
compris
infecti
diseas
often
forgotten
due
limit
incid
econom
incent
develop
prevent
treatment
nid
includ
common
chronic
infect
among
world
poorest
peopl
ec
support
vaccin
research
neglect
infecti
diseas
sinc
earli
project
total
ec
contribut
eur
mill
initi
project
address
divers
diseas
diarrhoeal
infect
hevar
lyme
diseas
bovac
otiti
media
omvac
helminth
infect
tranchi
scoott
project
mostli
smaller
strep
project
ec
contribut
eur
million
sinc
address
infecti
diseas
otherwis
neglect
project
impact
term
societ
valu
significantli
supersed
modest
size
possibl
creat
vaccin
host
noninfecti
diseas
cancer
neurodegen
diseas
autoimmun
diseas
provid
one
excit
field
current
vaccin
research
hold
potenti
meet
huge
unmet
medic
need
provid
altern
tradit
treatment
costli
partial
effect
associ
advers
effect
except
vaccin
project
alzheim
diseas
mimovax
effort
area
concentr
cancer
vaccin
project
target
major
cancer
lung
cancer
melanoma
carcinoma
project
mostli
focus
identif
specif
tumour
antigen
select
present
cancer
cell
therefor
provid
potenti
immun
target
vaccin
approach
largest
singl
project
cancerimmunotherapi
gather
partner
develop
therapeut
vaccin
melanoma
potenti
cancer
type
within
project
differ
vaccin
approach
test
compar
use
peptid
rna
immunogen
differ
type
immunolog
adjuv
dendrit
cell
field
vaccin
noninfecti
diseas
highli
promis
still
mani
fundament
roadblock
overcom
ec
fund
activ
basic
vaccinolog
undoubtedli
also
benefit
futur
advanc
vaccin
noninfecti
diseas
vaccin
contribut
enorm
public
health
use
appropri
implement
new
vaccin
public
health
sector
improv
use
exist
vaccin
critic
factor
optim
impact
vaccin
achiev
detail
understand
diseas
epidemiolog
vaccin
protect
necessari
furthermor
thorough
understand
socioeconom
benefit
individu
vaccin
must
support
decis
vaccin
campaign
final
research
health
personnel
must
receiv
appropri
suffici
train
obtain
better
understand
vaccinolog
impact
differ
vaccin
field
largest
singl
initi
clinic
vaccin
research
europris
networkofexcel
aim
europris
better
synergis
european
research
new
prevent
technolog
hivaid
includ
microbicid
vaccin
research
europris
network
creat
link
ongo
research
project
either
fund
european
commiss
fund
bodi
includ
bill
melinda
gate
foundat
total
network
compris
repres
institut
countri
anoth
noe
dcthera
focus
clinic
applic
vaccin
base
dendrit
cell
network
integr
activ
group
scientist
clinician
sme
order
translat
genom
proteom
bioinformat
inform
use
endpoint
clinic
trial
dcbase
therapi
cancer
hiv
ec
also
support
number
project
focu
network
activ
harmon
clinic
activ
eg
eurhavac
standard
research
method
eg
neutnet
project
activ
rel
small
budget
play
import
role
fill
gap
mani
research
activ
build
bridg
within
scientif
commun
final
import
aspect
human
capac
build
train
scientist
develop
countri
support
variou
way
dedic
project
advacec
coinfect
provid
theoret
field
train
respect
scientist
develop
countri
furthermor
sever
larger
project
eg
muvapr
emvda
integr
train
programm
fellowship
specif
earmark
train
scientist
develop
countri
great
success
vaccin
past
present
use
inspir
intensifi
research
area
life
scienc
even
number
import
infecti
diseas
hivaid
malaria
hepat
c
continu
escap
attempt
produc
effect
vaccin
vaccin
infecti
diseas
tb
exist
partial
effect
need
dramat
improv
respond
real
public
health
need
confront
challeng
vaccin
research
creation
strengthen
partnership
multipl
stakehold
necessari
one
character
featur
ec
framework
programm
strong
focu
cooper
research
differ
countri
around
research
group
countri
thu
particip
ongo
ec
support
vaccin
research
project
fig
framework
programm
histor
focus
integr
research
within
eu
major
particip
locat
eu
member
state
howev
increas
global
health
scienc
mean
particip
come
countri
either
neighbour
countri
europ
noneuropean
countri
trend
expect
becom
significantli
pronounc
framework
programm
programm
anoth
key
prioriti
partnership
scientist
differ
sector
signific
effort
therefor
made
identifi
research
area
appeal
public
privat
sector
result
industri
partner
join
vaccin
research
project
previou
framework
programm
industri
partner
includ
wide
rang
compani
rang
small
mediums
enterpris
sme
biotech
sector
largest
vaccin
manufactur
world
total
partner
vaccin
project
came
privat
industri
sector
vaccin
project
initi
typic
durat
year
therefor
still
progress
impress
result
alreadi
achiev
project
mani
result
expect
variou
project
evolv
come
year
begin
follow
introduct
seventh
framework
programm
health
research
play
equal
import
role
even
higher
averag
annual
budget
run
budget
alloc
eur
billion
cooper
health
research
correspond
annual
averag
approxim
eur
million
activ
povertyrel
diseas
hivaid
malaria
tb
remain
key
activ
activ
area
emerg
infecti
epidem
neglect
infecti
diseas
strengthen
area
emerg
infecti
epidem
fund
research
upcom
threat
european
health
viral
infect
activ
neglect
infecti
diseas
address
rang
protozo
bacteri
helminth
infect
signific
import
global
public
health
also
continu
support
research
clinic
applic
basic
vaccinolog
broad
applic
last
least
also
provid
continu
support
research
rang
noninfecti
diseas
vaccin
approach
becom
increasingli
relev
thu
potenti
sourc
sustain
support
wide
rang
vaccin
research
activ
furthermor
overal
focu
translat
research
health
theme
make
feasibl
mani
promis
result
vaccin
research
obtain
cours
acceler
translat
applic
